Our mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.
We are very pleased to be able to bring Suprax® an important anti-infective product in pediatric practice, back to the US market.
We are recognized as a leading manufacturer of cephalosporin API's, with FDA approval to manufacture complex oral and injectable cephalosporins.
Lupin is amongst the world's largest manufacturers of products in its chosen therapeutic areas.
Lupin Launches Generic Ortho Tri-Cyclen® Tablets in the US
Lupin Receives FDA Approval for Generic ctivella® Tablets
Lupin Receives FDA Approvals for Generic Vfend® Tablets
Lupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
Lupin Launches Generic Femhrt® Tablets in the US
Lupin Launches Generic Intermezzo® Sublingual Tablets in the US
Lupin Launches Generic Aricept® Tablets in the US
Lupin Completes its Acquisition of GAVIS in the US
Lupin Launches Generic Glumetza® HCI ER Tablets in the US
Lupin Receives FDA Approval for Generic Generess® Tablets
Lupin Receives FDA Approval for Generic Femhrt® Tablets
Lupin receives FDA Approval for Generic Aricept® Tablets
Lupin Launches Generic PhosLo® in the US
Lupin and Boehringer Ingelheim Announce Strategic Co-marketing Agreement
Lupin launches first ever Duloxetine 40mg Delayed-Release Capsules in the US
manufacturing / r&d
Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.